Detailed examination of fenfluramine-phentermine users with valve abnormalities identified in Fargo, North Dakota

American Journal of Cardiology

Volumn 84, Issue 3, 1999, Pages 304-308

  Kimmel, Stephen E ^a,b   Keane, Martin G ^a   Crary, Jack L ^c   Jones, Jane ^b   Kinman, Judith L ^b   Beare, Jeanne ^c   Sammel, Mary ^b   St John Sutton, Martin ^a   Strom, Brian L ^b  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c MeritCare Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERGOTAMINE; FENFLURAMINE; MIRTAZAPINE; PHENTERMINE; SEROTONIN RECEPTOR AFFECTING AGENT; SEROTONIN UPTAKE INHIBITOR; SUMATRIPTAN;

ADULT; ALLERGY; ARTICLE; CARDIOVASCULAR RISK; FEMALE; HEADACHE; HEART MURMUR; HUMAN; MALE; PRIORITY JOURNAL; RHEUMATIC FEVER; VALVULAR HEART DISEASE;

ADULT; APPETITE DEPRESSANTS; FEMALE; FENFLURAMINE; HEART VALVE DISEASES; HEART VALVES; HUMANS; MIDDLE AGED; NORTH DAKOTA; PHENTERMINE; RISK FACTORS;

EID: 0033179867     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)00281-7     Document Type: Article

References (24)

1. Connolly H.M., Crary J.L., McGoon M.D., Hensrud D.D., Edwards B.S., Edwards W.D., Schaff H.V. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 337:1997;581-588.
2. Griffen L., Anchors M. Asymptomatic mitral and aortic valve disease is seen in half of the patients taking "phen-fen" [letter] Arch Intern Med. 158:1998;102.
3. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services interim public health recommendations, November 1997. MMWR 1997;46:1061-1066.
4. Kurz X., Van Ermen A. Valvular heart disease associated with fenfluramine-phentermine. [letter] N Engl J Med. 337:1997;1772-1773.
5. Rasmussen S., Corya B.C., Glassman R.D. Valvular heart disease associated with fenfluramine-phentermine. [letter] N Engl J Med. 337:1997;1773.
6. Josefson D. US journal finds lower risk from diet pills. Br Med J. 315:1997;1329.
7. Newman R. Mitral valve disease associated with use of anorexigenic medications. [letter] Ann Thorac Surg. 64:1997;294.
8. Cannistra L.B., Davis S.M., Bauman A.G. Valvular heart disease associated with dexfenfluramine. [letter] N Engl J Med. 337:1997;636.
9. Jick H., Vasilakis C., Weinrich M.C., Meier C.R., Jick S.S., Derby L.E. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. N Engl J Med. 339:1998;719-724.
10. Weissman N.J., Tighe J.F. Jr, Gottdiener J.S., Gwynne J.T. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. N Engl J Med. 339:1998;725-732.
11. Khan M.A., Herzog C.A., St Peter J.V., Hartley G.G., Madlon-Kay R., Dick C.D., Asinger R.W., Vessey J.T. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. N Engl J Med. 339:1998;713-718.
12. Physicians Desk Reference. 52 ed. Montvale, NJ: Medical Economics Company, Inc., 1998:1956-1959.
13. Physicians Desk Reference. 52 ed. Montvale, NJ: Medical Economics Company, Inc., 1998:2826-2827.
14. Physicians Desk Reference. 52 ed. Montvale, NJ: Medical Economics Company, Inc., 1998:2420-2422.
15. Dechant K.L., Clissold S.P. Sumatriptan. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs. 43:1992;776-798.
16. Silberstein S.D. Serotonin (5-HT) and migraine. Headache. 34:1994;408-417.
17. Atkinson R.L., Blank R.C., Schumacher D., Dhurandhar N.V., Ritch D.L. Long-term drug treatment of obesity in a private practice setting. Obes Res. 5:1997;578-586.
18. Panconesi A., Sicuteri R. Headache induced by serotonergic agonists - a key to the interpretation of migraine pathogenesis? Cephalalgia. 17:1997;3-14.
19. Graham J.R., Suby H.I., LeCompte P.R., Sadowsky N.L. Fibrotic disorders associated with methysergide therapy for headache. N Engl J Med. 274:1966;359-368.
20. McCredie J., Kricker A., Elliott J., Forrest J. The innocent bystander doxylamine/dicyclomine/pyridoxine and congenital limb defects . Med J Aust. 140:1984;525-527.
21. Guess H.A., West R., Strand L.M., Helston D., Lydick E.G., Bergman U., Wolski K. Fatal upper gastrointestinal hemorrhage or perforation among users and nonusers of nonsteroidal anti-inflammatory drugs in Saskatchewan, Canada 1983. J Clin Epidemiol. 41:1988;35-45.
22. Strom B.L., Carson J.L., Halpern A.C., Schinnar R., Snyder E.S., Stolley P.D., Shaw M., Tilson H.H., Joseph M., Dai W.S., Chen D., Stolley P., Stern R., Bergman U. Using a claims database to investigate drug-induced Stevens-Johnson syndrome. Stat Med. 10:1991;565-576.
23. West S.L., Strom B.L., Freundlich B., Normand E., Koch G., Savitz D.A. Completeness of prescription recording in outpatient medical records from a health maintenance organization. J Clin Epidemiol. 47:1994;165-171.
24. Goodman M.T., Nomura A.M., Wilkens L.R., Kolonel L.N. Agreement between interview information and physician records on history of menopausal estrogen use. Am J Epidemiol. 131:1990;815-825.